Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting t...

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >...

Mastercard announced the launch of its Africa Cybersecurity Center of Excellence, a pan-African initiative designed to strengthen cyber resilience, enhance collaboration and help safeguard the trust that underpins Africa's expanding digital economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629910205/en/Michael Miebach, CEO, Mastercard unveiling The Cybersecurity Center of Excellence in Johannesburg, South Africa on Thursday...